8-K: Compass Therapeutics Reports Q2 2025 Results, Key Clinical Milestones

Compass Therapeutics announced its second quarter 2025 financial results and provided updates on its clinical pipeline, including promising data for CTX-8371 and a delay in tovecimig's overall survival data due to fewer patient deaths.

Summary

• Net loss for Q2 2025 was $19.9 million ($0.14 per share), an increase from $13.1 million ($0.10 per share) in Q2 2024.
• Research and Development (R&D) expenses increased by 47% to $16.4 million in Q2 2025, primarily due to manufacturing costs for tovecimig and CTX-10726.
• General and Administrative (G&A) expenses remained flat at $4.7 million for Q2 2025.
• Cash and marketable securities totaled $101 million as of June 30, 2025, providing an anticipated cash runway into 2027.
• The Phase 2/3 COMPANION-002 study for tovecimig in biliary tract cancer (BTC) met its primary endpoint of overall response rate (ORR) in April 2025, showing 17.1% ORR versus 5.3% for paclitaxel alone (p=0.031).
• Analysis of secondary endpoints (progression-free survival and overall survival) for tovecimig is now expected in Q1 2026, delayed from original projections due to fewer observed deaths in the study.
• The Phase 1 study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) showed two deep and confirmed partial responses in patients with non-small cell lung cancer (100% reduction) and triple-negative breast cancer (>90% reduction).
• Cohort expansions for CTX-8371 in non-small cell lung cancer and triple-negative breast cancer are planned to begin in Q4 2025.
• CTX-10726 (PD-1 x VEGF-A bispecific antibody) demonstrated superior anti-tumor effects and PD-1 inhibition compared to ivonescimab in preclinical mouse models.
• An Investigational New Drug (IND) filing for CTX-10726 is expected in Q4 2025, with clinical data anticipated in 2026.
• A Phase 2 trial for CTX-471 (CD137 agonist antibody) in patients with NCAM (CD56) expressing tumors is expected to initiate in the second half of 2025.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data, particularly for tovecimig and CTX-8371, indicating promising efficacy signals in ongoing trials. The extended cash runway into 2027 provides financial stability. While there's a delay in tovecimig's OS data, it's due to a positive reason (fewer deaths). The increased net loss and R&D expenses are typical for a clinical-stage biopharmaceutical company advancing its pipeline.

Positives

• Tovecimig's Phase 2/3 COMPANION-002 study met its primary endpoint of overall response rate (ORR) with 17.1% ORR versus 5.3% for paclitaxel alone (p=0.031).
• Fewer deaths than originally projected have been observed in the tovecimig study, which may suggest a positive effect on overall survival.
• CTX-8371 Phase 1 study showed two deep and confirmed partial responses, including a complete resolution of target lesions in a non-small cell lung cancer patient and over 90% reduction in a triple-negative breast cancer patient.
• CTX-8371 has been generally well tolerated with no dose-limiting toxicities observed to date.
• CTX-10726 demonstrated superior anti-tumor effects and PD-1 inhibition compared to ivonescimab, a leading candidate in its class, in preclinical models.
• The company ended Q2 2025 with $101 million in cash and marketable securities, providing a cash runway into 2027.
• Tovecimig was granted Fast Track Designation in BTC in April 2024.

Negatives

• Net loss increased to $19.9 million in Q2 2025 from $13.1 million in Q2 2024.
• Net loss per share increased to $0.14 in Q2 2025 from $0.10 in Q2 2024.
• Research and Development expenses increased significantly by 47% in Q2 2025, driven by manufacturing costs.

Risks

• Ability to raise additional funding needed to continue business and product development plans.
• Inherent uncertainties associated with developing product candidates and operating as a development stage company.
• Ability to identify additional product candidates for development.
• Ability to develop, initiate, and complete clinical trials for, obtain approvals for, and commercialize any product candidates.
• Competition in the industry in which the company operates.
• Market conditions impacting operations and financial performance.

Future Outlook

The company anticipates its current cash and marketable securities will fund operations into 2027. Key clinical milestones include the analysis of tovecimig's secondary endpoints (PFS/OS) in Q1 2026, initiation of CTX-8371 cohort expansions in Q4 2025 with data in 2026, IND submission for CTX-10726 in Q4 2025 with clinical data in 2026, and initiation of CTX-471 Phase 2 trial in H2 2025. The company also plans to report detailed Phase 1 dose-escalation study results for CTX-8371 at a medical conference in Q4 2025.

Management Comments

• "Following our previous announcement that the tovecimig Phase 2/3 trial met the primary endpoint of overall response rate, we are encouraged to see fewer deaths in the study than we originally modeled. Because the analysis of the secondary endpoints of progression-free survival and overall survival is triggered by total deaths in the study (80% pooled mortality), we are updating our guidance on the secondary endpoint analyses to Q1 2026."
• "In addition, we have observed two deep and confirmed partial responses (PRs) in the Phase 1 dose-escalation study of CTX-8371, our novel PD-1 x PD-L1 bispecific antibody. These responses included the complete resolution of measured target lesions in a patient with non-small cell lung cancer and over 90% reduction of measured target lesions in a patient with triple negative breast cancer. Both patients had extensive tumor burden at baseline and based on these signals of efficacy we are now planning to initiate the cohort expansion phase in patients with non-small cell lung cancer and triple-negative breast cancer in Q4."
• "CTX-10726, our PD-1 x VEGF bispecific antibody, is on track for IND submission in Q4 2025. We are happy to share initial preclinical data suggesting superiority to ivonescimab, a leading candidate in the class, in both PD-1 inhibition and anti-tumor activity in relevant mouse models. We believe CTX-10726 has the potential to be a differentiated drug candidate in this class."
• "Finally, our balance sheet remains strong, and we ended the quarter with $101 million, funding our operations into 2027."

Industry Context

The company operates in the highly competitive oncology biopharmaceutical sector, focusing on proprietary antibody-based therapeutics. Its pipeline targets critical biological pathways for anti-tumor responses, including angiogenesis, immune response activation, and immunosuppression alleviation. The development of bispecific antibodies like tovecimig, CTX-8371, and CTX-10726 positions the company within an innovative segment of cancer therapy, aiming for differentiated mechanisms of action. The focus on biliary tract cancer addresses a significant unmet medical need, with an estimated market potential exceeding $1 billion in the U.S. and approximately 85% of second-line patients lacking approved therapeutic alternatives.

Comparison to Industry Standards

• Tovecimig's 17.1% overall response rate (ORR) in second-line biliary tract cancer (BTC) compares favorably to historical data for paclitaxel alone (5.3% ORR in the study) and the ABC-06 study of FOLFOX chemotherapy (5% ORR, median OS of 6.2 months, <10% OS at 18 months). The COMPANION-002 study shows >20% overall survival (OS) at >17 months median follow-up, suggesting potential superiority.
• CTX-10726 demonstrated superior tumor control and PD-1 inhibition compared to ivonescimab, a leading PD-1 x VEGF-A bispecific antibody candidate, in head-to-head preclinical mouse models (human NSCLC HCC822 xenograft and MC38 transgenic models).
• CTX-10726's anti-PD-1 activity was comparable to pembrolizumab (Keytruda) in transgenic mouse models, indicating strong potential in checkpoint inhibition.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical trial data and extended cash runway, but also increased losses and R&D expenses.
• Patients: Promising new therapeutic options for difficult-to-treat cancers like biliary tract cancer, non-small cell lung cancer, and triple-negative breast cancer.
• Employees: Continued employment and potential growth opportunities as clinical programs advance.
• Creditors: Stable financial position with cash runway into 2027, reducing immediate liquidity concerns.

Next Steps

• Initiate Phase 2 basket study of tovecimig in broader DLL4+ cancers following secondary endpoint analyses from COMPANION-002 BTC trial.
• Continue active enrollment in Investigator Sponsored Trial (IST) of tovecimig at MD Anderson Cancer Center.
• Initiate cohort expansions for CTX-8371 in non-small cell lung cancer and triple-negative breast cancer in Q4 2025.
• Report detailed results from CTX-8371 Phase 1 dose-escalation study at a medical meeting in Q4 2025.
• Submit an IND for CTX-10726 in Q4 2025.
• Initiate a Phase 2 trial of CTX-471 in patients with NCAM (CD56) expressing tumors in H2 2025.

Key Dates

Recommendation

The filing presents compelling positive clinical data for multiple pipeline assets, particularly the efficacy signals for tovecimig and CTX-8371, and strong preclinical data for CTX-10726. The extended cash runway into 2027 is a significant positive for a clinical-stage company. However, the company is still pre-revenue with increasing net losses, and the delay in tovecimig's overall survival data, while for a positive reason, introduces a longer wait for definitive registrational data. Given the early stage of most programs and the inherent risks of drug development, a 'hold' recommendation is appropriate, acknowledging the strong potential while awaiting further clinical maturation and regulatory clarity.

Keywords

Biopharmaceutical, Oncology, Clinical-stage, Antibody therapeutics, Biliary tract cancer, Non-small cell lung cancer, Triple-negative breast cancer, Bispecific antibody, DLL4, VEGF-A, PD-1, PD-L1, CD137 agonist, Clinical trials, Drug development, Biotech, Cancer treatment